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   Evaiuation of therapeutic effects and endocrinoiogical studies of Estramustine Phosphate （Estracyt
IEMP） wcre made in 14 patients with prostatic carcinoma．
   Seven out of 14 patients without previous antiandrogenic medication showed objective response
to EMP treatment． In the other patients wlth relapse， one showed s呵ecしive response but 6 showed no
response te EMP treatment．
   Plas皿a LH， FSH， testosterone and 5α一dihyδrotestosterone were measured by a specific radio－
immunoassay in I O patients with prostatic carcinoma before and during EMP treatment． The clinical
statuses of the 10 patients were as follows ： Four had received no treatment before EMP administration s
namely fresh cases， the other 4 had been treated inadequately； namely false reactivated cases and
the remainder were true reactivated cases．
   Plasma testosterone， 5a－dihydrotestosterone and gonadotropins concentrations decreased sig－
nificantly in frcsh cases and false reactivatedi cases． The cases of true reactivation showed no change
in plasma testosterone and 5a－dihydrotestosterone levels after administration of EMP．
   Fro皿the results mcntioned above， it was noted that． no signi丘cant differcnce． of hormonal effect
was found between oral administration of560 mgfday EM？， 200 ipg／day diethylstilbesterol－diphosphate
and 30 mg／day hexestrol．’





















































































   （転移のない症例）


































   （転移のある症例）
症例 年齢 投与量 期問
転 移 巣 原発巣
肺 リンパ 骨 大きさ 硬さ
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症例年齢 治療歴  投与量 期間
転 移 巣 原発巣
肺 1ルパ 骨 大きさ硬さ





EE2 9 M 6Tab 3 M
CMA 22M      6Tab 3 MEE2 5 M
CMA 39M 6Tab 3 M
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PL SMA T LEVELS IN PAT［ENTS WiTH PROSTATIC CARCINOMA
        BEFoRE AND DuRING EMP TREATMEN丁









LEVELS ［N PAT［ENTS WITH PROSTATIC CARCINOMA








PRE 1  2     3
Fig． 2
4 WEEKs
PLASMA DHT LEvELs ］N pATIENTs wlTH PROSTATiC
         BEFORE AND DuR［NG EMP TREA丁MEN丁 NG／DL





PRE 1  2
Fig． 4
3 4 WEEKs




 PしASMA LH LE・vELS IN PATIENTS PROSTATIC CARC［NOMA
 BEFORE AND DuRING EMP 丁REATMENT







PRE 1 2 4
Fig． 5
PLAsMA FSH LEvELs【N PA丁IENTs wlTH PRosTATATIC cARclNoMA
BEFORE AND DURING EMP TREATMENT































































































 3．EMP 560 mgは血中丁， DHT， FSH， LHの
変動より見て，DES－Dip 2001ng， Hex 30 mgに相当
する作用を持つ薬剤と思われた．
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濫発   ．レ用法・腿・日・回，4・mlを灘内・・闘する・
                       年齢，症状により適宜増減する。
   ■グリチルリチン製剤．
   多亜力；承オミ／7ア1＿ゲγγ＿
                 包装20ml 5管・3噌，5m‘5項目．5曙，．2mi 1噌・10噌
                ⇒使用上の注意な．どについては，添付文書をご参照下さい。
                   o内服薬．．』躍盟畳四7；錠二号
                              包装 100錠，1000錠，5000錠．     嚇難ミノフナーゲン製薬本舗〔〒16。〕．東京都縮区縮3刊．
